Sp573
EXPANDING THERAPY FOR THE HYPERCONTRACTILE ESOPHAGUS
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
This session provides a deeper understanding of how and when to use our current state of the art tools for physiology testing. Audience members will appreciate the nuances of esophageal motility reading, when to order which pH test for reflux symptoms. This session will also focus on the currently identified esophageal motility disorders as per the Chicago Classification version 4.0. This will highlight potential therapeutic options for these disorders. Attendees will hear about non-achalasia motility disorders and focus on current studies that highlight treatment of Ineffective Esophageal Motility, Distal Esophageal Spasm, Achalasia, Esophagogastric Junction Outflow Obstruction, Absent Contractility, and Hypercontractile Esophagus.
This session provides a deeper understanding of how and when to use our current state of the art tools for physiology testing. Audience members will appreciate the nuances of esophageal motility reading, when to order which pH test for reflux symptoms. This session will also focus on the currently identified esophageal motility disorders as per the Chicago Classification version 4.0. This will highlight potential therapeutic options for these disorders. Attendees will hear about non-achalasia motility disorders and focus on current studies that highlight treatment of Ineffective Esophageal Motility, Distal Esophageal Spasm, Achalasia, Esophagogastric Junction Outflow Obstruction, Absent Contractility, and Hypercontractile Esophagus.
Presenter
University of Michigan
Tracks
Related Products
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
AGA Optimizing Outcomes in Patients with Refractory GERD
GERD refractory to standard therapy is a common problem in clinical practice. The causes are multiple and there is a need for a rational evidence based approach to this problem…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
